1.
A pregnancy test should be performed in all cases of persistent or irregular vaginal bleeding after a pregnancy event ( particularly after 6 weeks) 2. Suction evacuation is the preferred initial management regardless of uterine size. Ideally this should be performed by an experienced Obstetrician / Gynaecologist. 3. In selected cases a second evacuation may be necessary for histological confirmation in difficult cases and / or because of the problematic bleeding, but it has been shown that there is still a 70% chance of requiring chemotherapy and an 8% chance of uterine perforation. 4. Repeat curettage is not recommended if hCG > 5000 or in the presence of metastases. 5. All products of conception obtained at evacuation should be sent for histology. 6. Vaginal gestational trophoblastic neoplasia is most commonly located in the fornices or suburethrally. Due to their highly vascular nature, biopsy should be avoided. 7. Ploidy status and immunohistochemistry staining for P57 may be useful for differentiation between a partial or complete mole. 8. Use of prostaglandins to ripen the cervix is appropriate. 9. Avoid oxytocic use until after evacuation. 10. It is recommended that all patients who are RhD negative receive RhD Immunoglobulin prophylaxis. 11. To minimise the risk of perforation of the uterus , insertion of an intrauterine device should be delayed for at least 6 weeks after evacuation of the uterus and the hCG levels have returned to normal. 12. One person or team should be made responsible for the patient regarding monitoring of hCG levels. 13. A gynaecologist should undertake the monitoring of the post evacuation hCG levels and counselling of the patient. 14. Oestrogen and/or progestogens taken between evacuation of the mole and return to normality of hCG values appear NOT to increase the risk of invasive mole or choriocarcinoma developing. Therefore, women may use oral \ contraceptives after molar evacuation, before hCG returns to normal. Pregnancy should be avoided until after the completion of the surveillance period 1 . 15. A diagnosis of a gestational choriocarcinoma and PSTT requires referral to the Gynaecologic Oncology team. 16. For women who conceive again there is a 1: 70 chance of having a subsequent molar pregnancy. An ultrasound scan early in pregnancy at 6 weeks gestation is recommended. Also obtain hCG levels 6 weeks after the conclusion of any future pregnancy, regardless of outcome. 17. Follow up shall occur in the Emergency Centre.
BACKGROUND 1
Gestational Trophoblast Disease (GTD)forms a spectrum of illnesses that are rare, almost always highly curable but not always well understood by non-specialists. The types of trophoblast disease range from the usually benign partial molar pregnancy through complete molar pregnancy and invasive mole to the malignant choriocarcinoma and placental site trophoblast tumours. All of these illnesses share the characteristic that they arise from a pregnancy.
Gestational trophoblastic neoplasia (GTN) is a term used to describe GTD requiring chemotherapy or excisional treatment because of the persistence of hCG or the presence of metastases.GTN follow hydatidifiorm mole (60%), previous miscarriage / abortion (30%), normal pregnancy or ectopic gestation (10%) 2
CLASSIFICATION
The World Health Organisation classification divides trophoblast disease into the premalignant and malignant forms as shown below:-
PRE-MALIGNANT TROPHOBLAST DISEASE

Molar Pregnancy
The incidence of molar pregnancies in Europe and North America is in the order of 0.2-1.5 per 1000 live births although these figures are of limited accuracy. There may be a higher incidence of molar pregnancies in Africa and Asia; however the varying standards in the frequency and accuracy of pathology and demographics make accurate comparisons difficult.
\
The relative risk of molar pregnancy is highest in those pregnancies at the extremes of the reproductive age group. There is a modestly increased incidence in teenagers (1.3 fold) but a 10 fold increased risk in those aged 40 and over. The risk of a complete molar pregnancy increases more than the risk of developing a partial mole.
Historically the relative incidence of partial and complete molar pregnancies has been reported as approximately 3:1000 and 1:1000. This situation may well represent an over diagnosis of partial mole as data from CXH demonstrates that nearly 40% of partial moles referred for expert review are reclassified as either complete moles or non-molar pathologies.
Partial Mole
Partial moles are triploid with 2 sets of paternal and 1 set of maternal chromosomes.
Macroscopically partial moles may resemble the normal products of conception with initially an embryo present, which dies by week 8-9. The histology shows less swelling of the chorionic villi than in complete mole and there are usually only focal changes. As a result the diagnosis of partial mole can often be missed after an apparently straightforward miscarriage or termination.
The clinical presentation of partial mole is most frequently via irregular bleeding or by detection on routine ultrasound. The obstetric management is by suction or medical evacuation and these all partial mole patients should be followed up with serial hCG.
Partial moles rarely become malignant with generally only one or two cases of malignant disease seen per year at CXH with an overall risk of 0.5% of requiring chemotherapy after a partial mole.
Complete Mole
In most complete moles the genetic material is entirely male in origin and results from the fertilisation of an empty ovum lacking maternal genes. The chromosome complement is most commonly 46XX, which results from one sperm that duplicates its DNA, or less frequently 46XX or 46XY from the presence of two different sperm. On very rare occasions complete moles can be biparental with genetic contributions from both the mother and father (ref) . Whilst this type is extremely rare, biparental mole is associated with a high risk of further molar pregnancies and patients who have had more than 2 molar pregnancies may benefit from investigation at an expert centre.
The diagnosis of complete mole is most often made as a result of bleeding, a large for dates uterus, or an abnormal ultrasound. Macroscopically there is no fetus and the histology shows the characteristic oedematous villous stroma. However the textbook 'bunch of grapes' appearance is seen in the second trimester and as now most cases are diagnosed earlier, this is rarely seen. The obstetric management is by suction evacuation followed by serial hCG measurement and surveillance registration.
\
In contrast to a partial mole, a complete mole more frequently proceeds to invasive disease with 8-20% of patients requiring chemotherapy.
MALIGNANT TROPHOBLAST DISEASE Invasive Mole (chorioadenoma destruens)
Invasive mole is a very rare condition. The use of routine ultrasound, the early evacuation of complete moles and effective hCG surveillance means that very few women have this diagnosis.
Invasive mole usually arises from a complete mole and is characterised by invasion of the myometrium, which can lead to perforation of the uterus. Microscopically invasive mole has a similarly benign histological appearance as complete mole but is characterised by the ability to invade in to the myometrium and the local structures if untreated.
The usual presentation is with hCG elevations following a previous molar pregnancy; other clinical features can include abnormal bleeding, abdominal pain or swelling.
Gestational Choriocarcinoma
Choriocarcinoma is clinically and histologically overtly malignant and presents the most common emergency medical problems in the management of trophoblast disease.
The diagnosis most frequently follows a complete mole when the patients are usually in a surveillance programme but can also arise in unsupervised patients after a nonmolar abortion or a normal pregnancy.
The clinical presentation of choriocarcinoma can be from the disease locally in the uterus leading to bleeding, or from distant metastases that can cause a wide variety of symptoms with the lungs, central nervous system and liver the most frequent sites of distant disease.
Choriocarcinoma presenting with distant metastases can present some diagnostic challenges, however the combination of the reproductive/gynaecology history and elevated serum hCG usually makes the diagnosis apparent and so avoid a biopsy which can be hazardous from the risk of haemorrhage.
On the occasions that pathology is available the characteristic findings show the structure of the villous trophoblast but with sheets of syncytiotrophoblast or cytotrophoblast cells, haemorrhage, necrosis and intravascular growth is common.
In contrast to molar pregnancies the genetic profile of choriocarcinoma gives a range of gross abnormalities without any specific characteristic pattern.
Placental Site Trophoblastic Tumour (PSTT) \
Placental site trophoblast tumours were first described in 1976 (Kurman 1976) and are the least common form of gestational trophoblast disease comprising less than 2% of all cases. PSTT most commonly follows a normal pregnancy but may occur after a non-molar abortion or a complete molar pregnancy.
In contrast to the other types of trophoblast disease which characteristically present fairly soon after the index pregnancy, in PSTT the average interval between the prior pregnancy and presentation is 3.4 years. The clinical presentation of PSTT can range from slow growing disease limited to the uterus to more rapidly growing metastatic disease that is similar in behaviour to choriocarcinoma.
The most frequent presentations are abnormal bleeding or amenorrhea. Usually the hCG levels, whilst elevated, are relatively low in PSTT relative to the volume of the disease compared to the other types of GTT.
PSTT is diploid and arises from the non-villous trophoblast and the pathology is characterised by intermediate trophoblastic cells with vacuolated cytoplasm, the expression of PLAP rather than hCG and the absence of cytotrophoblast and villi.
Postpartum and Infantile Choriocarcinoma
Choriocarcinoma is an uncommon but curable cancer that develops during pregnancy and although it most often occurs with a complete hydatidiform mole, may occur after a normal pregnancy. Postnatal women who present with persistent postpartum bleeding which does not appear to be related to the recent pregnancy should be tested to exclude choriocarcinoma. This may include 4. Send all products of conception for histology examination and consider cytogentics 5. Administer RhD immunoglobulin to Rh-negative patients after surgery.
FOLLOW UP NB: Normal levels = < 5iu/L
• Following diagnosis patients should be followed by weekly serial serum hCG levels.
•
Complete moles
Weekly quantative hCG levels should be undertaken until 3 consecutive normal levels are achieved and then monthly levels should be performed for a further 6 months following normalisation. If during follow up any level is > 5iu/L this must be reported to the consultant responsible for the woman's care
• Partial moles Weekly quantative hCG levels should be taken until 3 consecutive normal levels are achieved. If it takes less than 8 weeks to achieve normalisation the patient may be discharged without any further follow up.
If normalisation takes more than 8 weeks to be achieved the patient should have monthly quantative hCG levels performed for a further 6 months from the time of normalisation. If during follow up any result is > 5iu/L this must be reported to the consultant responsible for the woman's care
• Send a discharge letter to the GP. Provide information of discharge, the follow-up management and include management if the woman presents with a future pregnancy.
